No Data
Express News | Fulcrum Therapeutics Inc. : Oppenheimer Cuts Target Price to $14 From $16
Goldman Sachs Upgrades Fulcrum Therapeutics to Buy From Neutral, Price Target Is $15
Fulcrum Therapeutics (FULC) has an average rating of outperform and price targets ranging from $5 to $19, according to analysts polled by Capital IQ. Price: 7.80, Change: +0.45, Percent Change: +6.12
Express News | HC Wainwright & Co. Reiterates Buy on Fulcrum Therapeutics, Maintains $17 Price Target
Buy Rating Affirmed for Fulcrum Therapeutics: Licensing Deal With Sanofi and Promising Phase 3 Study
Fulcrum Therapeutics Is Maintained at Outperform by Oppenheimer
Fulcrum Therapeutics Is Maintained at Outperform by Oppenheimer
Express News | Oppenheimer Maintains Outperform on Fulcrum Therapeutics, Lowers Price Target to $14